Maze Therapeutics Inc (MAZE) Stock Price, Quote & News

Company Profile

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 850 5070

Website: www.mazetx.com

Address:

171 Oyster Point Blvd, Suite 300, South San Francisco, United States

StocktwitsNews Sep. 22 at 5:01 PM

Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder $VRTX $MAZE https://stocktwits.com/news/equity/markets/twin-moves-vrtx-rises-on-kidney-disease-trial-results-maze-rallies-harder/cZMPusmRB7c

1 · Reply

mysterio99 Sep. 22 at 4:38 PM

$VBIO here we go! 🚀🚀🚀🚀 $DCOY $IMCC $MAZE $JAGX

0 · Reply

notreload_ai Sep. 22 at 3:58 PM

Truist calls $VRTX Phase 2b inaxaplin data a validation of APOL1 inhibition in AMKD and sees a 100,000+ extra patient opportunity, plus positive readthrough for $MAZE . https://notreload.xyz/xy/vertex-inaxaplin-data-widens-amkd-market-lifts-maze/

0 · Reply

ajmrtxl Sep. 22 at 3:30 PM

$MAZE 's latest squeeze play

0 · Reply

stockydennis Sep. 22 at 2:51 PM

$MAZE but coloma keeps dumping,

0 · Reply

Windy007 Sep. 22 at 2:36 PM

$MAZE 10:29 AM Truist analyst Danielle Brill views Vertex's (VRTX) positive Phase 2 topline data as a meaningful validation of APOL1 inhibition in classic APOL1-mediated kidney disease and estimates the data supports a potential addressable population of greater than 100,000 patients. The firm, which sees the data having "a significant positive readthrough" for Maze Therapeutics (MAZE), adds that while it remains too early to draw conclusions regarding relative efficacy, it believes the size of the opportunity is large enough to support blockbuster sales potential for MZE829 even if it ultimately demonstrates efficacy and safety comparable to inaxaplin. Truist has a Buy rating and $64 price target on Maze shares, which are up about 25% to $28.00 in morning trading.

0 · Reply

Mmssmm Sep. 22 at 2:22 PM

$MAZE what is the catalyst for this stock rising??!! I can’t find any news??!!

0 · Reply

onlyGreenPlz Sep. 11 at 8:31 PM

Is $MAZE a buyout candidate? I know it’s too early to say but wondering what people thought.

0 · Reply

AlphaResearchHQ Aug. 7 at 4:10 PM

JUST UPDATED ITS STOCK PORTFOLIO 📊 (Part 3) More positions from Google’s Q2 portfolio update: 🤖 $PATH — 7,034,337 shares 🧬 $PRME — 16,562,498 shares 🧪 $MAZE — 1,388,583 shares 💊 $RLAY — 1,410,029 shares 🚀 $BBOT — 2,823,126 shares This part of the portfolio shows continued exposure to emerging technology, automation, and biotech innovation. Institutional portfolios are always worth studying because they can reveal where long-term investors are willing to allocate capital. These names may not all move immediately, but understanding the themes behind the investments can provide valuable insight. I’ll continue tracking these companies and watching how the market reacts as these sectors develop. Save this one and revisit it when the market gives us the next signal.

0 · Reply

EquityResearch6 Aug. 7 at 2:47 PM

GOOGLE $GOOGL JUST UPDATED ITS STOCK PORTFOLIO. Here are the major holdings as of the end of Q2: $GTLB — GitLab 2,724,712 shares $PATH — UiPath 7,034,337 shares $PRME — Prime Medicine 16,562,498 shares $MAZE — Maze Therapeutics 1,388,583 shares Google’s portfolio shows exposure across several long-term innovation themes. Big technology companies often invest years ahead of mainstream adoption. Watching where companies like Google deploy capital can provide insight into the future technology landscape. Follow my profile for more AI, space, and next-generation technology trends. NFA. DYOR.

0 · Reply

Maze Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Sep 10, 2026, 2:20 PM EDT - 12 days ago

Maze Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026

Sep 9, 2026, 9:30 AM EDT - 13 days ago

Maze Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference

Sep 2, 2026, 7:00 AM EDT - 20 days ago

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

Aug 13, 2026, 4:42 PM EDT - 5 weeks ago

Maze Therapeutics Announces Appointments to Its Board of Directors

2026-08-11T20:16:47.000Z - 6 weeks ago

Maze Therapeutics reports Q2 EPS (76c), consensus (70c)

Aug 11, 2026, 4:01 PM EDT - 6 weeks ago

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Aug 11, 2026, 4:00 PM EDT - 6 weeks ago

Maze Therapeutics Earnings release: Q2 2026

Aug 11, 2026, 4:00 PM EDT - 6 weeks ago

Maze Therapeutics Quarterly report: Q2 2026

Jun 10, 2026, 8:40 AM EDT - 3 months ago

Maze Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 12:00 PM EDT - 3 months ago

Maze Therapeutics Transcript: AGM 2026

Jun 3, 2026, 3:45 PM EDT - 3 months ago

Maze Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 7:00 AM EDT - 3 months ago

Maze Therapeutics Slides: Investor presentation

May 27, 2026, 7:03 AM EDT - 3 months ago

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

2026-05-12T21:36:39.000Z - 4 months ago

Maze Therapeutics reports Q1 EPS (45c), consensus (63c)

May 12, 2026, 4:01 PM EDT - 4 months ago

Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

May 12, 2026, 4:00 PM EDT - 4 months ago

Maze Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:00 PM EDT - 4 months ago

Maze Therapeutics Quarterly report: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Maze Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Maze Therapeutics Proxy statement: Proxy filing

2026-04-22T12:10:05.000Z - 5 months ago

Maze Therapeutics priced offering of 5.54M shares of common stock at $23.50

Apr 22, 2026, 7:00 AM EDT - 5 months ago

Maze Therapeutics Slides: Corporate presentation

Apr 22, 2026, 12:09 AM EDT - 5 months ago

Maze Therapeutics Announces $150 Million Registered Offering

2026-04-14T11:17:48.000Z - 5 months ago

Maze Therapeutics price target lowered to $64 from $68 at Truist

2026-03-31T10:51:36.000Z - 5 months ago

Maze Therapeutics price target raised to $58 from $52 at JPMorgan

Mar 26, 2026, 9:40 AM EDT - 6 months ago

MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-03-25T16:00:16.000Z - 6 months ago

Maze Therapeutics falls -29.8%

2026-03-25T15:36:01.000Z - 6 months ago

Maze Therapeutics share sell-off an ‘overreaction,’ says Raymond James

VRTX

2026-03-25T14:06:47.000Z - 6 months ago

Maze Therapeutics falls -33.2%

2026-03-25T13:36:15.000Z - 6 months ago

Leerink remains bullish on Maze, says Vertex comparison ‘apples to oranges’

VRTX

2026-03-25T13:25:30.000Z - 6 months ago

Maze Therapeutics price target raised to $110 from $60 at H.C. Wainwright

2026-03-25T12:07:43.000Z - 6 months ago

Maze Therapeutics reports Q4 EPS (65c), consensus (78c)

2026-03-25T12:07:27.000Z - 6 months ago

Maze Therapeutics up 15% at $56.43 after Q4 results and MZE829 trial data

2026-03-25T12:00:48.000Z - 6 months ago

Maze Therapeutics announces positive topline data from Phase 2 HORIZON Trial

Mar 25, 2026, 8:00 AM EDT - 6 months ago

Maze Therapeutics Transcript: Study result

Mar 25, 2026, 8:00 AM EDT - 6 months ago

Maze Therapeutics Press release: Study result

Mar 25, 2026, 8:00 AM EDT - 6 months ago

Maze Therapeutics Slides: Study result

Mar 25, 2026, 7:00 AM EDT - 6 months ago

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

Mar 25, 2026, 7:00 AM EDT - 6 months ago

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Mar 25, 2026, 7:00 AM EDT - 6 months ago

Maze Therapeutics Annual report: Q4 2025

Mar 25, 2026, 7:00 AM EDT - 6 months ago

Maze Therapeutics Earnings release: Q4 2025

2026-03-17T20:16:50.000Z - 6 months ago

Maze Therapeutics initiated with a Buy at Truist

2026-03-16T12:00:26.000Z - 6 months ago

Maze Therapeutics price target raised to $58 from $43 at Wedbush

Mar 4, 2026, 10:30 AM EST - 6 months ago

Maze Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 7:00 AM EST - 6 months ago

Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 11, 2026, 3:00 PM EST - 7 months ago

Maze Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:00 AM EST - 7 months ago

Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 12, 2026, 11:15 AM EST - 8 months ago

Maze Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 8 months ago

Maze Therapeutics Slides: Corporate presentation

Jan 5, 2026, 7:00 AM EST - 8 months ago

Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 10:25 AM EST - 9 months ago

Maze Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 20, 2025, 7:00 AM EST - 10 months ago

Maze Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 2:00 PM EST - 10 months ago

Maze Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 8:00 AM EST - 10 months ago

Maze Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 4:01 PM EST - 10 months ago

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 6, 2025, 4:00 PM EST - 10 months ago

Maze Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 10 months ago

Maze Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

Nov 5, 2025, 6:00 PM EST - 10 months ago

Maze Therapeutics Slides: Corporate Presentation

Nov 4, 2025, 7:00 AM EST - 10 months ago

Maze Therapeutics to Participate in Four Upcoming Investor Conferences

Oct 28, 2025, 4:27 PM EDT - 10 months ago

Maze Therapeutics CEO Jason Coloma on how the new biotech is taking on Kidney disease

Oct 28, 2025, 12:36 PM EDT - 10 months ago

San Francisco is making a comeback. So are these stocks from the City by the Bay

NKTR REAL

Oct 17, 2025, 8:00 AM EDT - 11 months ago

Maze Therapeutics Registration statement: Registration Filing

Oct 6, 2025, 7:00 AM EDT - 11 months ago

Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

Sep 11, 2025, 8:30 AM EDT - 1 year ago

Maze Therapeutics Transcript: Study Result

Sep 11, 2025, 8:30 AM EDT - 1 year ago

Maze Therapeutics Press release: Study Result

Sep 11, 2025, 8:30 AM EDT - 1 year ago

Maze Therapeutics Slides: Study Result

Sep 11, 2025, 7:35 AM EDT - 1 year ago

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

Sep 11, 2025, 7:30 AM EDT - 1 year ago

Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

Sep 2, 2025, 7:00 AM EDT - 1 year ago

Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer

Aug 27, 2025, 11:31 AM EDT - 1 year ago

National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry

Aug 12, 2025, 4:01 PM EDT - 1 year ago

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Maze Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Maze Therapeutics Quarterly report: Q2 2025

Jun 3, 2025, 4:00 PM EDT - 1 year ago

Maze Therapeutics Slides: Corporate Presentation

May 29, 2025, 7:30 AM EDT - 1 year ago

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference

May 14, 2025, 4:01 PM EDT - 1 year ago

Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones

May 14, 2025, 4:00 PM EDT - 1 year ago

Maze Therapeutics Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Maze Therapeutics Earnings release: Q1 2025

May 13, 2025, 7:30 AM EDT - 1 year ago

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference

Mar 31, 2025, 4:00 PM EDT - 1 year ago

Maze Therapeutics Annual report: Q4 2024

Mar 31, 2025, 4:00 PM EDT - 1 year ago

Maze Therapeutics Earnings release: Q4 2024

Mar 31, 2025, 7:30 AM EDT - 1 year ago

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights

Feb 7, 2025, 8:00 AM EST - 1 year ago

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

Jan 31, 2025, 12:33 PM EST - 1 year ago

Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut

Jan 30, 2025, 7:45 PM EST - 1 year ago

Biotech firm Maze Therapeutics raises $140 million in US IPO

Jan 30, 2025, 7:30 PM EST - 1 year ago

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

Jan 30, 2025, 7:00 AM EST - 1 year ago

Maze Therapeutics Registration statement: Registration Filing

Jan 27, 2025, 7:00 AM EST - 1 year ago

Maze Therapeutics Registration statement: Registration Filing

Jan 27, 2025, 6:31 AM EST - 1 year ago

Maze Therapeutics targets up to $728 mln valuation in US IPO

StocktwitsNews Sep. 22 at 5:01 PM

1 · Reply

mysterio99 Sep. 22 at 4:38 PM

$VBIO here we go! 🚀🚀🚀🚀 $DCOY $IMCC $MAZE $JAGX

0 · Reply

notreload_ai Sep. 22 at 3:58 PM

0 · Reply

ajmrtxl Sep. 22 at 3:30 PM

$MAZE 's latest squeeze play

0 · Reply

stockydennis Sep. 22 at 2:51 PM

$MAZE but coloma keeps dumping,

0 · Reply

Windy007 Sep. 22 at 2:36 PM

0 · Reply

Mmssmm Sep. 22 at 2:22 PM

$MAZE what is the catalyst for this stock rising??!! I can’t find any news??!!

0 · Reply

onlyGreenPlz Sep. 11 at 8:31 PM

Is $MAZE a buyout candidate? I know it’s too early to say but wondering what people thought.

0 · Reply

AlphaResearchHQ Aug. 7 at 4:10 PM

0 · Reply

EquityResearch6 Aug. 7 at 2:47 PM

0 · Reply

stockydennis Jul. 27 at 4:33 PM

$MAZE so good

0 · Reply

stockydennis Jul. 24 at 5:33 PM

$MAZE otsuka sanofi Novartis Someone is buying $MAZE shortly .

0 · Reply

MikeCaymanTrades Jul. 5 at 2:49 AM

$MAZE Signal Update Today's recommendation from our system is to STAY LONG. The previous BUY signal was issued on 06/17/2026, 15 days ago, when the stock price was 24.41. Since then, MAZE has risen by +28.06%. Weekly chart very bullish.

0 · Reply

Olena Jun. 26 at 9:42 PM

$MAZE Poet Technologies (NASDAQ: POET) remains highly volatile and speculative. While the stock has seen massive percentage gains in 2026, it is currently in a steep downward correction, recently falling to roughly $9.68 per share amid broader semiconductor sell-offs, profit-taking, and investor concerns about commercial scaling

0 · Reply

svertical1 Jun. 9 at 3:13 PM

$MAZE $VRTX https://grok.com/share/c2hhcmQtMw_5c39ece5-ad7b-4374-a2fa-b3ca117c10b3 Both look great!

1 · Reply

justiceforb_85 Jun. 9 at 5:07 AM

$MAZE anyone with insight on why MZR829 versus inaxaplin by $VRTX?

0 · Reply

SuperGreenToday May. 26 at 5:19 PM

$MAZE Share Price: $25.95 Contract Selected: Jan 15, 2027 $35 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.80 – $0.97 Potential Upside: 77% ROI Time to Expiration: 233 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

AnthonyTradingWithJesus Apr. 27 at 4:08 AM

$AI $MAZE $JOB $OMEX $CRM Good interview, very bullish, very transparent

1 · Reply

almlk Apr. 8 at 2:11 PM

$SPY $QQQ Start seeing RED in my watch list: $PLTR is the first RED followed by $APP, $MAZE Others start retreating from highs, decrease their gains.

0 · Reply

StreetwiseReports Apr. 7 at 5:17 PM

San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial https://ow.ly/YB7J50YF5RP H.C. Wainwright reiterated its rating and price target on Maze Therapeutics ( $MAZE ), following KOL calls that validated the HORIZON Phase 2 dataset as biologically coherent, confirmed the diabetic cohort signal as drug-attributable proof of concept, and outlined a clear path to pivotal trials.

0 · Reply

Quantumup Apr. 2 at 12:12 PM

Guggenheim⬇️ $UNCY's PT to $40, reiterated at Buy and said, We had a chance to catch up with the Unicycive management team yesterday after the company released their 4Q 2025 results earlier in the week. $MAZE TVTX SNY TAK $ARDX Here's what else Guggenheim had to say: https://x.com/Quantumup1/status/2039676564908945610?s=20

0 · Reply

Market Cap	1.25B
Revenue (ttm)	0.00
Net Income (ttm)	-131.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.11

Volume	3,565,284
Avg Vol	435,506
Day's Range	N/A - N/A
Shares Out	55.55M
Stochastic %K	10%
Beta	2.17
Analysts	Strong Sell
Price Target	$62.55